Latest phenytoin Stories

2014-08-07 15:44:44

The JAMA Network Journals Researchers have identified genetic variants that are associated with severe adverse skin reactions to the antiepileptic drug phenytoin, according to a study in the August 6 issue of JAMA. Phenytoin is a widely prescribed antiepileptic drug and remains the most frequently used first-line antiepileptic drug in hospitalized patients. Although effective for treating neurological diseases, phenytoin can cause cutaneous (skin) adverse reactions ranging from mild to...

2014-07-23 08:31:01

- Brivaracetam is the newest investigational medicine to emerge from UCB's rich late-stage pipeline BRUSSELS, July 23, 2014 /PRNewswire/ -- regulated information -- UCB today announced an important advance in its research and development pipeline with positive topline results from the latest Phase 3 study with brivaracetam. This study was designed to evaluate the efficacy and safety of brivaracetam (100 and 200 mg/day, without titration) compared to placebo, as adjunctive treatment in adult...

2014-07-18 23:01:32

Transparency Market Research added a new report "Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/epilepsy-therapeutics-market.html. (PRWEB) July 18, 2014 Epilepsy is a group of long-term neurological disorders that is characterized by recurring seizures. These seizures are episodes that occur when group of nerve cells or neurons in brain sends...

2014-06-17 00:20:31

WOODCLIFF LAKE, N.J., June 16, 2014 /PRNewswire/ -- Eisai Inc. announced today that a Phase III clinical trial (study 332) of its in-house-discovered AMPA receptor antagonist perampanel has met its primary endpoint in patients with primary generalized tonic-clonic (PGTC) seizures, a severe form of seizures. http://photos.prnewswire.com/prnvar/20120413/MM87168LOGO Study 332 was a double-blind, randomized, placebo-controlled, multicenter, parallel-group trial to evaluate the efficacy and...

2014-06-13 23:03:11

According to a recently published research letter from JAMA, the severe cutaneous reactions are typically experienced following use of a broad array of prescription and over-the-counter medications. Port Washington, New York (PRWEB) June 13, 2014 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs is commenting on a study that reveals that the risk of repeat episodes of Stevens-Johnson syndrome (SJS) and toxic epidermal...

2014-04-25 08:27:40

WOODCLIFF LAKE, N.J., April 25, 2014 /PRNewswire/ -- Eisai Inc. announced today that six abstracts highlighting data analyses for FYCOMPA(TM) (perampanel) will be presented at the 66(th) annual American Academy of Neurology (AAN) meeting, taking place in Philadelphia, PA from April 26( )- May 3. http://photos.prnewswire.com/prnvar/20120413/MM87168LOGO "Eisai and its epilepsy franchise are committed to expanding its knowledge of current products and developing new medications for the...

2014-04-02 23:30:03

Flood Law Group today announced that they are available to investigate claims of birth defects such as cleft palates or cleft lips that could be related to the use of the prescription drug Topamax during pregnancy. The FDA issued a Drug Safety Communication about use of topiramate (the generic version of Topamax) in 2011. Washington, D.C. (PRWEB) April 02, 2014 Flood Law Group announced today that they are now actively investigating claims on behalf of parents whose children were born...

2014-01-02 08:23:03

FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist WOODCLIFF LAKE, N.J., Jan. 2, 2014 /PRNewswire/ -- Eisai Inc. announced today that FYCOMPA(TM) (perampanel) CIII will be available to eligible patients by prescription in the U.S. beginning January 6, 2014. FYCOMPA is an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy age 12 years and older. FYCOMPA is...

Word of the Day
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'